688266 泽璟制药
2024/06 - 中期
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额112,553(232,751)(370,343)(454,623)(343,857)
投资活动产生之现金流量净额35,58864,839(264,056)326,657(499,253)
筹资活动产生之现金流量净额44,3651,509,366282,79293,9941,899,039
汇率变动对现金及现金等价物的影响372174,068(1,438)(3,794)
现金及现金等价物净增加/(减少)192,5431,341,671(347,539)(35,410)1,052,135
期初现金及现金等价物余额2,077,777736,1061,083,6451,119,05566,920
期末现金及现金等价物余额2,270,3202,077,777736,1061,083,6451,119,055